<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04189094</url>
  </required_header>
  <id_info>
    <org_study_id>IRB-2019-164</org_study_id>
    <nct_id>NCT04189094</nct_id>
  </id_info>
  <brief_title>Chemoradiotherapy With or Without Sintilimab in Limited-stage SCLC</brief_title>
  <official_title>Chemoradiotherapy With or Without Sintilimab in Limited-stage Small Cell Lung Cancer: a Multicenter Prospective Randomized Phase II Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zhejiang Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>First Affiliated Hospital, Sun Yat-Sen University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Affiliated Hospital of Guangdong Medical College</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First People's Hospital of Foshan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Zhejiang Cancer Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is a prospective, multi-center, open-label, randomized, and controlled phase II
      clinical trial.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 1, 2020</start_date>
  <completion_date type="Anticipated">July 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>2 years</time_frame>
    <description>PFS, defined as the time from the date of randomization to the first date of documented objective progression disease or of death from any cause.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>5 years</time_frame>
    <description>OS, measured from the date of randomization to the date of death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall response rates</measure>
    <time_frame>2 years</time_frame>
    <description>ORR, tumor response will be measured by using the RECIST 1.1.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">140</enrollment>
  <condition>Small Cell Lung Cancer Limited Stage</condition>
  <arm_group>
    <arm_group_label>Sintilimab + CRT arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with limited-stage SCLC receive etoposide and cisplatin (carboplatin) plus Sintilimab induction therapy for 2 cycles and then receive thoracic radiotherapy (45 Gy/30 fractions) with concurrent EP/EC chemotherapy for 2cycles. Patients who achieve CR or PR then receive prophylactic cranial irradiation (PCI, 25 Gy/10 fractions). After PCI, Sintilimab maintenance therapy will be administered once every 3 week for 13 cycles.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CRT arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients with limited-stage SCLC receive etoposide and cisplatin (carboplatin) for 2 cycles and then receive thoracic radiotherapy (45 Gy/30 fractions) with concurrent EP/EC chemotherapy for 2cycles. Patients who achieve CR or PR then receive prophylactic cranial irradiation (PCI, 25 Gy/10 fractions).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sintilimab</intervention_name>
    <description>Etoposide and cisplatin (carboplatin) plus Sintilimab induction therapy will be administered for 2 cycles and then thoracic radiotherapy (45 Gy/30 fractions) be administered with concurrent EP/EC chemotherapy for 2cycles. Patients who achieve CR or PR then receive prophylactic cranial irradiation (PCI, 25 Gy/10 fractions).Sintilimab maintenance therapy will be administered once every 3 week for 13 cycles.</description>
    <arm_group_label>Sintilimab + CRT arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etoposide</intervention_name>
    <description>Etoposide will be administered IV 100mg/m2 on days 1-3, 22-24, 43-45 and 64-66.</description>
    <arm_group_label>CRT arm</arm_group_label>
    <arm_group_label>Sintilimab + CRT arm</arm_group_label>
    <other_name>VP-16</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>cisplatin will be administered IV 80mg/m2 on days 1, 22, 43 and 64.</description>
    <arm_group_label>CRT arm</arm_group_label>
    <arm_group_label>Sintilimab + CRT arm</arm_group_label>
    <other_name>DDP</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiotherapy</intervention_name>
    <description>Thoracic radiotherapy (45 Gy/30 fractions) and prophylactic cranial irradiation (25 Gy/10 fractions).</description>
    <arm_group_label>CRT arm</arm_group_label>
    <arm_group_label>Sintilimab + CRT arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Histologically/cytologically confirmed diagnosis of SCLC.

          2. Radiologically (including brain CT/MRI, chest and abdomen contrasted CT and bone
             scintigraphy. PET/CT is recommended) confirmed limited-stage.

          3. Patients should be ≥ 18 years old.

          4. ECOG performance status of 0-1 (Karnofsky performance status ≥ 80).

          5. With adequate cardiac, pulmonary, bone marrow, hepatic and renal function.

          6. With weight loss no more than 10% within 6 months before diagnosis.

          7. Informed consent must be signed.

        Exclusion Criteria:

          1. Histology confirmed the mixed NSCLC components;

          2. Other primary malignant tumors appeared within 5 years before the first administration
             of the study drug, except for locally curable malignant tumors after radical treatment
             (such as basal or squamous cell skin cancer, superficial bladder cancer or prostate,
             cervical or breast carcinoma in situ, etc.);

          3. Any disease or condition contraindicated by radiotherapy or chemotherapy;

          4. Malignant pleural effusion and pericardial effusion;

          5. Pregnant and lactating women;

          6. History of idiopathic pulmonary fibrosis (IPF), including pneumonia and organic
             pneumonia;

          7. Received live vaccination within 28 days before the first administration of the study
             drug;

          8. 28 days prior to the first administration of the study drug, he participated in any
             other drug clinical trials or is undergoing other clinical trials.

          9. Have received any antibody / drug (including PD-1, PDL1, CTLA4, tim3, Lag3, etc.)
             targeting T-cell co regulatory protein (immunocheckpoint).

         10. The investigator believes that the subject's complications or other circumstances may
             affect the compliance with the protocol or may not be suitable for the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ming Chen, MD. PhD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cancer Hospital of the University of Chinese Academy of Science (Zhejiang Cancer Hospital)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ming Chen, MD. PhD.</last_name>
    <phone>86-571-88122199</phone>
    <email>chenming@zjcc.org.cn</email>
  </overall_contact>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>November 27, 2019</study_first_submitted>
  <study_first_submitted_qc>December 4, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 6, 2019</study_first_posted>
  <last_update_submitted>December 4, 2019</last_update_submitted>
  <last_update_submitted_qc>December 4, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 6, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>radiotherapy</keyword>
  <keyword>chemotherapy</keyword>
  <keyword>immunotherapy</keyword>
  <keyword>PD-1 inhibitor</keyword>
  <keyword>lung cancer</keyword>
  <keyword>small cell</keyword>
  <keyword>limited-stage</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Small Cell Lung Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Etoposide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

